文献速递湿疹皮炎与荨麻疹

阿布昔替尼诱导应答者维持治疗优化:JADE REGIMEN事后分析

Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-05-16

JADE REGIMEN事后分析纳入对阿布昔替尼200 mg诱导治疗12周应答的中重度特应性皮炎患者,随机接受200 mg、100 mg或安慰剂维持40周。基线体表面积较低、无既往系统治疗史及诱导后EASI改善幅度较大可预测维持期不复发,支持部分患者采用100 mg减量维持。

要点

  • 基线体表面积较低、无既往系统治疗史及EASI改善幅度大预测维持期不复发。
  • EASI自基线至诱导结束的变化幅度是维持期不复发概率的主要贡献因素。
  • 基线病情较轻且对200 mg诱导应答强者可考虑100 mg减量维持。

核心结论

  • 对基线病情较轻且对阿布昔替尼200 mg诱导治疗应答强的患者,采用100 mg减量维持可能可行。

研究设计与样本

  • JADE REGIMEN(NCT03627767)3期试验的事后分析,纳入对阿布昔替尼200 mg诱导12周应答并随机接受200 mg、100 mg或安慰剂维持40周的患者。

主要发现

  • 基线体表面积较低(p=0.09)、无既往系统治疗暴露(p=0.02)及EASI自基线至随机化的百分比变化较大(p<0.001)为阿布昔替尼维持期不复发的预测因素。
  • 在两个阿布昔替尼治疗臂中,EASI自基线至诱导结束(第12周)的百分比变化是维持期不复发概率的主要贡献因素。

关键数值与推荐

  • 基线体表面积较低与不复发相关(p=0.09)。
  • 无既往系统治疗暴露与不复发相关(p=0.02)。
  • EASI自基线至随机化的百分比变化较大与不复发相关(p<0.001)。

临床怎么用

  • 对基线病情较轻且对阿布昔替尼200 mg诱导应答强的患者,可考虑100 mg减量维持以平衡疗效与不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment optimization may require dosing flexibility. The Phase 3 JADE REGIMEN trial (NCT03627767) evaluated maintenance of abrocitinib 200 mg-induced response in patients with moderate-to-severe atopic dermatitis (AD) randomly assigned to subsequent maintenance with continuous-dose abrocitinib (200 mg), reduced-dose abrocitinib (100 mg) or placebo. Maintenance with continuous-dose abrocitinib was associated with a stronger prevention of disease flares, but also with a higher occurrence of adverse events, compared with the reduced dose. OBJECTIVE: This post hoc analysis of JADE REGIMEN aimed to identify predictors of not flaring during the maintenance period and to generate tools that can be used to assess probability of not flaring. METHODS: Data were analysed from patients who responded to abrocitinib 200 mg induction therapy (12 weeks) and were randomly assigned to receive abrocitinib (200 mg or 100 mg) or placebo in the 40-week maintenance period. Demographic and baseline disease characteristics and level of response to induction were evaluated for association with not flaring using logistic regression. Parameters with a significant (p < 0.15) interaction with the treatment arm were fitted into a multivariable regression model, which was used to assess probability of not flaring. RESULTS: Lower percentage body surface area affected at baseline (p = 0.09), absence of prior exposure to systemic agents (p = 0.02) and greater percentage change in EASI from baseline to randomization (p < 0.001) were identified as predictors of not flaring with abrocitinib. In both abrocitinib arms, percentage change in EASI from baseline to end of induction (Week 12) was the major contributor to the probability of not flaring in the maintenance period. CONCLUSIONS: Maintenance of response using reduced-dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Thyssen JP, Silverberg JI, Ruano J, et al. Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN. J Eur Acad Dermatol Venereol. 2024. PMID: 38752592. doi:10.1111/jdv.20095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。